Apr 2, 2022
MediSieve Receives Industry Recognition
MediSieve, a biotech company that has developed an innovative blood filtration device, receives recognition and approval from the industry.
Upstream, an Industrial Strategy co-produced by Hammersmith & Fulham Council and Imperial College London, has recognised MediSieve as one of the Innovation and Impact 110 (II110) organisations. The II110 is a definite list of changemakers and pioneers in science, tech, creative as well as charitable sectors. The organisation is driven by the belief that local networks facilitate collaboration and learning and, hence, can accelerate the growth of organisations and places. MediSieve has been partnering with Upstream for a long time now as part of the White City's innovation district and is grateful to be part of such an inclusive and thriving ecosystem of ambitious science, tech and creative organisations and start-ups.
MediSieve was also recognised in the European Tech For Good Report 2022. The world's leading Tech recruiter Hays Technology partnered with start-up super connectors Empact Ventures and created the Super Connect for Good competition, an incredible contest that saw tech start-ups from across the UK, Ireland and Europe pitch to become the best-of-the-best in their categories of innovation. The competition included a 100 start-ups and scale-ups creating positive social change with each application being carefully examined by a team of judges over four rounds. After careful considerations, MediSieve's treatment that can detect and remove harmful bacteria and toxins from a patient’s bloodstream selectively without causing immunosuppression, was chosen as an overall champion. MediSieve is delighted for such an award and hopes to live up to the title. The company's CEO Dr George Frodsham said:
"We were delighted to be the Overall Winner of the Super Connect for Good competition and it felt fantastic to see the subsequent piece on MediSieve in the European Tech for Good Report. We're excited about the potential impact of our technology, which could be lifesaving for some of our patients and news like this drives us to continue our push towards success."
Industry recognition means a lot for the company both by increasing publicity and by reminding the good MediSieve's technology can do on rough days. The company is grateful and will not take the awards for granted!
More information on II110 can be found here:
https://www.move-upstream.org.uk/impact-and-innovation-110/
The full European Tech For Good Report 2022 can be found here:
https://www.hays.co.uk/it/super-connect-for-good
About Magnetic Blood Filtration
MediSieve's Magnetic Blood Filtration Platform is intended to enable the rapid and specific depletion of specific agents from the bloodstream of patients. The extracorporeal therapy uses therapeutic Magnetic Beads that are designed to bind specifically to the clinical target. The Beads are introduced into the extracorporeal circuit during the therapy, mixing with the patient’s blood and binding to the clinical targets. The Delivery Platform captures all the Magnetic Beads and bound targets, preventing their return to the patient.
About MediSieve
MediSieve is a London-based BioTech start-up that has developed Magnetic Blood Filtration, a revolutionary platform therapy that enables the physical removal of specific substances from the bloodstream of patients. It can be used (1) as a direct treatment, (2) to increase the safety and efficacy of other therapies, or (3) to enable personalised medicine. The company is a spin-off from University College London and is developing its products at the White City Innovation District in West London. MediSieve is actively seeking investment and partnerships.
MEDIA CONTACT:
Alina Kagermazova
INVESTOR AND PARTNERSHIP CONTACT:
George Frodsham
